Abivax SA’s Ulcerative Colitis Drug On Track for 2025

Abivax SA (FR:ABVX) has released an update.

Abivax SA, a biotech firm, has reached a significant milestone in its Phase 3 ABTECT Trial for obefazimod, a drug candidate for ulcerative colitis, with over 600 patients enrolled and on track for full enrollment by early Q1 2025. Positive data from Phase 2 trials have propelled the global Phase 3 program, and a Phase 2b trial for Crohn’s disease is slated to begin in Q3 2024.

For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.